ProPhase Labs, Inc. Q4 FY2023 earnings call

Management Statement and Operational Highlights

• Pharmaloz: Profitable since Q1 2024, increased prices in Q4 2023, announced new lozenge lines, installed automation equipment, and is in discussions with multiple global brands for capacity expansion.
• Nebula Genomics: Revamped marketing, built a lab in New York, has a proprietary reporting system, and Jason Karkus serves as president, driving B2B opportunities.
• Leadership: Ted Karkus as CEO, Jed Latkin as COO, Jason Karkus leading Nebula, and a strong finance and IT team in place.
• Strategic Initiatives: Transitioned from COVID testing, focused on Pharmaloz's growth, expanded Nebula's B2B efforts, developed the BE-Smart test, and planned for Equivir's rollout.

Segment Performance

• Pharmaloz: Historically generated $8-10M in revenue, last year over $9M. Increased prices in Q4 2023, becoming profitable. Expected to reach a $15-16M run rate in Q2, with plans to expand capacity, aiming for a $45M+ run rate by Q3 and potentially $90-100M+ with additional lozenge lines.
• Nebula Genomics: Focused on direct-to-consumer whole genome sequencing with a revamped marketing campaign. Built a lab in New York for B2B opportunities, announced the first B2B deal, and has significant interest from large businesses, including a telemedicine platform with 2,000 physicians and 6-8M patients.
• BE-Smart esophageal cancer test: A cutting-edge test with no competition, holding multi-billion dollar potential.
• Equivir: Broad-based antiviral in preclinical studies, expected to roll out in the second half of 2024.

Guidance

• Pharmaloz: Anticipates reaching a $45M+ run rate by Q3, with potential for a $90-100M+ capacity by year-end, aiming for 20-25% net profit margins.
• Nebula Genomics: B2B deals expected to ramp up in the second half, with significant revenue growth from large contracts.
• BE-Smart and Equivir: Development ongoing, with Equivir set to roll out in the second half of 2024, and the BE-Smart test holding multi-billion dollar potential.

Risks

• Regulatory: Uncertainty around obtaining and maintaining necessary regulatory approvals for products like BE-Smart and Equivir.
• Competition: Potential competition from larger labs and DNA companies, though Nebula has unique proprietary elements.
• Economic: General economic conditions affecting consumer demand for products and services.
• Execution: Challenges in executing on strategic initiatives, such as timing of B2B deals and capacity expansion.

Question and Answer

• Q: What is the competitive advantage of Nebula Genomics in the WGS arena? A: Unique lab in the US, proprietary bioinformatics, reliable turnaround times, great pricing, backing from George Church and Russ Altman, and access to new equipment not available elsewhere.
• Q: How long is the sales cycle for Pharmaloz customers? A: Varies; larger brands have longer cycles due to FDA inspections, audits, etc., but smaller brands may move quicker. Currently in discussions with 4 significant brands.
• Q: When is ProPhase expected to be profitable? A: Pharmaloz is profitable now; Nebula is in a development stage with significant investment, but B2B deals are expected to drive revenue and profitability in the future.
• Q: What is the sales process for the BE-Smart test? A: Possible partnerships with major cancer testing companies or insurance mandates; no competition, with unique proprietary proteins.
• Q: How does ProPhase compete with major labs like Quest and 23andMe? A: Nebula has a unique reporting system, lower pricing, and better turnaround; Quest/LabCorp are not in the same B2B business yet, and 23andMe studies less DNA compared to Nebula's whole genome sequencing.